Biller Jonathan 4

What Happened

• Jonathan Biller, Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals (VRTX), disposed of shares via a tax/exercise-related transaction and an open-market sale. On 2026-02-24, 1,144 shares were surrendered/used to satisfy an exercise price or tax liability at $485.11 per share (proceeds/value reported as $554,966). On 2026-02-25, 945 shares were sold in the open market at $486.35 per share for $459,601. Combined proceeds/value of the transactions are about $1.01 million. Both actions are disposals (sales), which are generally routine for executives managing option exercises and tax obligations.

Key Details

• Transaction dates and prices:
  • 2026-02-24: 1,144 shares at $485.11 (code F — payment of exercise price or tax liability) — $554,966.
  • 2026-02-25: 945 shares sold open-market at $486.35 (code S) — $459,601.
• Total shares disposed: 2,089; combined value ≈ $1,014,567.
• Shares owned after the reported transactions: not specified in the provided filing summary.
• Footnote: The 02/24 transaction was made pursuant to Mr. Biller’s company‑approved Rule 10b5-1 trading plan entered on 02/24/2025.
• Filing: Form 4 filed 2026-02-26 for transactions on 02/24–02/25 — appears to be timely (no late filing indicated).

Context

• The code F entry usually means shares were surrendered to cover the exercise price or tax withholding tied to an option exercise or vested award. The subsequent open-market sale of 945 shares likely reflects disposition of additional shares after the exercise/withholding.
• These are disposals (sales) rather than purchases; sales often reflect routine tax management or option exercises and are not, by themselves, a clear signal of changed executive sentiment.
• No indication from the filing that Mr. Biller is a 10% owner; this is executive-level insider activity.